Bioverativ (BIVV) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free BIVV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 25, 2023 | morningstar.comBiogen Inc 0R1B Stock QuoteApril 1, 2023 | nasdaq.comEDU Crosses Above Average Analyst TargetDecember 17, 2022 | thestreet.comBioverativ Makes Splash in Trading Debut, Gaining 18% on Day OneAugust 14, 2022 | seekingalpha.comAmarin Stock: Potential Risks And Rewards (NASDAQ:AMRN) - Seeking AlphaAugust 5, 2022 | marketscreener.comManagement to host conference call today at 4:30 p.m. ET - Form 8-K - Marketscreener.comAugust 4, 2022 | finance.yahoo.comCuris Reports Second Quarter 2022 Financial Results and Business Update - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Yahoo FinanceJuly 28, 2022 | businesswire.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Business WireJuly 21, 2022 | law360.comChancery Holding Amplifies Approach To Boardroom Issues - Law360June 14, 2022 | finance.yahoo.comNeuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors - Yahoo FinanceMay 27, 2022 | law360.comNo Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal - Law360April 28, 2022 | globenewswire.comPress Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 - GlobeNewswireApril 4, 2022 | businesswire.comGlobal Next Generation Complement Therapeutics Market Report 2022-2035: Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, RoA - ResearchAndMarkets.com - Business WireApril 1, 2022 | prnewswire.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - PR NewswireMarch 31, 2022 | finance.yahoo.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - Yahoo FinanceMarch 30, 2022 | finance.yahoo.comCold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight - Yahoo FinanceMarch 21, 2022 | businesswire.comWorldwide Gene Editing Beyond CRISPR Industry to 2035 - Featuring Amgen Ventures, ArrowMark Partners and Baxter Ventures Among Others - ResearchAndMarkets.com - Business WireMarch 19, 2022 | globenewswire.comHormone Refractory Prostate Cancer Market Size [2022-2028] - GlobeNewswireMarch 17, 2022 | finance.yahoo.comHormone Refractory Prostate Cancer Market Size [2022-2028] to Reach USD 18.35 Billion and Exhibit a CAGR of 9.64% | The Brainy Insights - Yahoo FinanceFebruary 22, 2022 | streetinsider.comSigilon Therapeutics (SGTX) Appoints Sarah Yuan as Chief Technical Operations Officer - StreetInsider.comJanuary 5, 2022 | finance.yahoo.comCrinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A. - Yahoo FinanceNovember 30, 2021 | prnewswire.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - PRNewswireNovember 29, 2021 | streetinsider.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - StreetInsider.comNovember 15, 2021 | forbes.comThe Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship - ForbesOctober 12, 2021 | globenewswire.commRNA Synthesis and Manufacturing Services Market Report 2021-2030 - GlobeNewswireOctober 12, 2021 | prnewswire.commRNA Synthesis and Manufacturing Services Markets, 2021-2030: Success of the Anti-COVID-19 Vaccines has Created an Enormous Need for Consistent Supply of These New Vaccines - PRNewswireOctober 5, 2021 | businesswire.comGlobal Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness - ResearchAndMarkets.com - Business WireSeptember 8, 2021 | streetinsider.comFulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer - StreetInsider.comAugust 8, 2021 | prnewswire.comBioTheryX Announces Appointments of Three New Members to its Board of Directors - PRNewswireAugust 8, 2021 | markets.businessinsider.comBioTheryX Announces Appointments of Three New Members to its Board of Directors - Markets InsiderJuly 22, 2021 | benzinga.comBiogen: Q2 Earnings Insights - Benzinga Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now BIVV Media Mentions By Week BIVV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVV News Sentiment▼0.000.95▲Average News Sentiment BIVV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVV Articles This Week▼00▲BIVV Articles Average Week Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVV) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioverativ Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
